Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Milei Threatens Falkland Oil Firms With Sanctions 
OpenAI Nears Astra AI Model Launch With Safety Focus 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., March 05, 2018 -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ:GBT) today announced that on March 1, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 7,500 shares of the Company’s common stock with a per share exercise price of $58.80, the closing trading price on the grant date, and restricted stock units for an aggregate of 4,950 shares of the Company’s common stock. All of the above-described awards were made under the Company’s 2017 Inducement Equity Plan (the "Plan").
The above-described awards were each granted as an inducement material to the employees’ entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock options and restricted stock unit awards described above) for issuance under the Plan, which was approved by the Company’s Board of Directors in January 2017.
About Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
